(IN BRIEF) GSK has entered an agreement to acquire Canadian biotechnology company 35Pharma for $950 million in order to strengthen its pipeline of therapies for pulmonary hypertension and related cardiopulmonary diseases. The acquisition includes HS235, an investigational activin signalling inhibitor … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 35Pharma, activin signalling inhibitor, biotechnology acquisition, CANADA, cardiopulmonary diseases, clinical trials, drug development, GSK, GSK Targets Next Generation Pulmonary Hypertension Treatments with Acquisition of 35Pharma, GSK to Acquire 35Pharma for 950 Million Dollars to Strengthen Pulmonary Hypertension Drug Pipeline, HS235, Ilia Tikhomirov, PH-HFpEF, pharmaceutical industry, pulmonary arterial hypertension PAH, pulmonary hypertension, Respiratory Immunology and Inflammation portfolio, Tony Wood
(IN BRIEF) Novartis has announced plans to establish a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, with operations expected to begin in 2028. The new site will expand the company’s U.S. manufacturing network and support growing demand for targeted … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged advanced manufacturing, bioengineering jobs, cancer treatment manufacturing, Dallas Fort Worth biotech, Denton Texas, Greg Abbott, Novartis, Novartis Expands Radioligand Therapy Network with New Manufacturing Site in Denton Texas, Novartis Strengthens US Radioligand Therapy Production with Planned Texas Manufacturing Investment, nuclear medicine, oncology pipeline, pharmaceutical manufacturing, radioligand therapy RLT, radiopharmaceuticals, targeted radiation therapy, US investment program, Vas Narasimhan
Ad hoc announcement pursuant to Art. 53 LR (IN BRIEF) Basilea Pharmaceutica has been awarded USD 6 million by the Biomedical Advanced Research and Development Authority to continue development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Security & Safety, Switzerland
Tagged antibiotic development, antimicrobial resistance, ASPR, BARDA, Basilea Advances Antibiotic Pipeline with BARDA Funding for Oral Beta Lactam Combination Therapy, Basilea Pharmaceutica, Basilea Receives USD 6 Million BARDA Funding to Advance Development of Oral Antibiotic for Drug Resistant Urinary Infections, beta lactam beta lactamase inhibitor, ceftibuten ledaborbactam etzadroxil, complicated urinary tract infections cUTI, Cresemba®, David Veitch, FDA Fast Track designation, multidrug resistant bacteria, pyelonephritis, Qualified Infectious Disease Product QIDP, US Department of Health and Human Services, Zevtera®
(IN BRIEF) The European Commission has approved Ranluspec, a ranibizumab biosimilar developed by Lupin and commercialized by Sandoz, for the treatment of neovascular age-related macular degeneration and several other retinal disorders. The therapy has demonstrated comparable efficacy and safety to … Read the full press release
Posted in Business, European Union, Healthcare, Marketing, News, Pharma & Biotech, Switzerland
Tagged access to medicines, Afqlir, Basel Switzerland, biosimilars Europe, choroidal neovascularization, diabetic macular edema, diabetic retinopathy, EU commercialization rights, European Commission approval, eye disease treatment, Lucentis reference medicine, lupin, neovascular age-related macular degeneration, ophthalmology treatments, pharmaceutical partnership, ranibizumab biosimilar, Ranluspec, retinal vein occlusion, Sandoz, Sandoz and Lupin Advance European Market Entry for Ranluspec Following Regulatory Clearance, Sandoz Secures European Approval for Ranluspec to Expand Access to Biosimilar Treatment in Retinal Diseases
(IN BRIEF) Aalborg University has joined forces with Aarhus University and quantum technology company Kvantify in the ODAQS project, a DKK 17.4 million initiative funded by Innovation Fund Denmark to make quantum computing more practical for pharmaceutical research. The project … Read the full press release
Posted in Artificial Intelligence (AI), Denmark, Education, Healthcare, Management, News, Pharma & Biotech, Science, Society, Technology
Tagged Aalborg University, Aarhus University, Allan Grønlund, Christian Schilling, Danish research collaboration, drug discovery, Grand Solutions programme, Healthcare Innovation, Innovation Fund Denmark, Innovation Fund Denmark Backs Quantum Software Development to Unlock Faster and More Cost Efficient Pharmaceutical Research, Jaco van de Pol, Kim Guldstrand Larsen, Kvantify, New Collaboration Between Universities and Kvantify Targets Software Breakthroughs for Real World Quantum Computing, ODAQS project, optimized compilation, pharmaceutical research, programming languages, quantum algorithms, quantum chemistry, quantum computing, quantum software stack, quantum technology development, reinforcement learning, software verification
(IN BRIEF) Data presented at EAPCI Summit 2026 analysing 21 European countries found no significant link between higher national rates of primary PCI procedures and reduced mortality following myocardial infarction, suggesting that access alone does not determine outcomes. The research … Read the full press release
Posted in Business, Education, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Ali Malik, cardiometabolic risk, cardiovascular disease, EAPCI Summit 2026, ESC Atlas of Cardiology, European Association of Percutaneous Cardiovascular Interventions, European healthcare data, European Society of Cardiology, healthcare systems research, interventional cardiology, King’s College London, mortality analysis, Mount Sinai Health System, myocardial infarction, New Multi Country Study Highlights Systemic Factors Beyond Procedure Numbers in Reducing Cardiovascular Mortality, Pan European Data Review Points to Prevention Expertise and Care Pathways as Key Drivers of Cardiac Outcomes, percutaneous coronary intervention, Prevention Strategies, primary PCI, Sanjay Sivalokanathan, Sukruth Pradeep Kundur
(IN BRIEF) DHL Group has strengthened its Life Sciences & Healthcare logistics offering by expanding a dedicated Airfreight Cold Chain Network as part of a EUR 2 billion investment in DHL Health Logistics. The enhanced network integrates global aviation capacity, … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Transportation & Logistics
Tagged airfreight expansion, Boeing 777 freighter, BRUcargo, Brussels Cincinnati corridor, cold-chain network, DHL Expands Dedicated Airfreight Cold Chain Network to Strengthen Global Healthcare Logistics, DHL Group, DHL Health Logistics, DHL Invests in Expanded Cold Chain Airfreight Network to Meet Growing Global Demand for Healthcare Logistics, EUR 2 Billion Health Logistics Investment Drives Launch of Advanced Cold Chain Connectivity Between Key Pharma Markets, GDP compliant hubs, global pharma distribution, healthcare logistics investment, Life Sciences and Healthcare logistics, pharmaceutical transport, supply chain resilience, temperature sensitive shipping, temperature-controlled logistics, vaccines biologics cell and gene therapies
(IN BRIEF) Sandoz has joined two new multi-buyer virtual Power Purchase Agreements in Europe under Schneider Electric’s Energize programme, working with suppliers to support new renewable energy projects and expand access to clean electricity. The agreements build on a previous … Read the full press release
Posted in Business, Energy, Gas & Oil, Environment, Financial, France, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Pharma & Biotech, Switzerland, Technology
Tagged Becton Dickinson and Company, clean energy collaboration, Energize programme, European renewable projects, Gerresheimer Group, greenhouse gas reduction strategy, healthcare sustainability, Lynn De Proft, renewable electricity procurement, Sandoz, Sandoz Expands Renewable Energy Strategy Through New European Virtual Power Purchase Agreements with Key Suppliers, Schneider Electric, Scope 2 emissions reduction, supply chain decarbonization, virtual power purchase agreement
(IN BRIEF) Novartis announced positive Phase III results from the RemIND trial showing that the oral BTK inhibitor remibrutinib achieved significantly higher complete response rates than placebo in three major forms of chronic inducible urticaria. The treatment demonstrated good tolerability … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Angelika Jahreis, autoimmune and inflammatory diseases, BTK inhibitor, chronic inducible urticaria, chronic urticaria treatment, CIndU, dermatology innovation, FDA application, global clinical trials, histamine pathway, immunology research, Novartis, Novartis Advances Immunology Pipeline with Promising Late Stage Outcomes for Oral BTK Inhibitor in Rarely Addressed Skin Disorder, Phase III study, regulatory submission, remibrutinib, RemIND trial, Rhapsido, targeted therapy development
(IN BRIEF) Roche has appointed physician-scientist Mark Dawson as Head of Pharma Research and Early Development, effective 1 May 2026, with the role based in Basel and including membership on the Enlarged Corporate Executive Committee. Dawson brings extensive expertise in … Read the full press release
(IN BRIEF) Eckert & Ziegler and the Nuclear Physics Institute of the Czech Academy of Sciences have scaled up production of the critical medical isotope Actinium-225, moving from development into larger-scale manufacturing at facilities in Řež and Braunschweig. The expansion … Read the full press release
Posted in Business, Czech Republic, Financial, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged Actinium-225, Braunschweig production, CDMO services, Eckert & Ziegler, Gallium-68, isotope supply chain, Lutetium-177, nuclear medicine, Nuclear Physics Institute Czech Academy of Sciences, oncology innovation, Partnership Advances Commercial Production of Actinium-225 for Next Generation Nuclear Medicine Applications, radioisotope production, radiopharmaceuticals, Řež facility, targeted alpha therapy, TecDAX listed company, Yttrium-90
(IN BRIEF) Roche reported that its phase III MAJESTY trial met its primary endpoint, showing that treatment with Gazyva/Gazyvaro enabled significantly more patients with primary membranous nephropathy to achieve complete remission at two years compared with tacrolimus. The study also … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Security & Safety, Switzerland, Technology
Tagged anti-CD20 monoclonal antibody, autoimmune kidney disease, B cell depletion therapy, clinical trial phase III, European Medicines Agency, FDA, Gazyva, Gazyvaro, idiopathic nephrotic syndrome, immunology pipeline, kidney function preservation, lupus nephritis, MAJESTY study, MAJESTY Trial Success Positions Gazyva for Possible First Approval in Primary Membranous Nephropathy Treatment, obinutuzumab, primary membranous nephropathy, remission outcomes, renal disease research, Roche, systemic lupus erythematosus
(IN BRIEF) Sanofi reported new real-world evidence showing that immunization with Beyfortus can significantly reduce RSV-related hospitalizations not only during an infant’s first RSV season but also into the second year of life. The NIRSE-GAL study in Galicia, Spain, demonstrated … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Retail, Science, Security & Safety, Technology
Tagged Beyfortus, early lung protection, Federico Martinón Torres, Galicia Spain, hospitalization reduction, infant immunization, infant respiratory health, lower respiratory tract infection, monoclonal antibody, New Published Data Reinforce Value of Universal Infant RSV Immunization in Reducing Hospital Burden, NIRSE GAL study, nirsevimab, pediatric prevention, public health strategy, real-world evidence, RSV respiratory syncytial virus, RSVVW 26 Rome, Sanofi, The Lancet Infectious Diseases, Thomas Triomphe
(IN BRIEF) Novartis has reported final Phase III ALIGN study results showing that Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy compared with placebo. At Week 136, the therapy demonstrated a 2.39 ml/min/1.73m² difference in eGFR change … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged accelerated approval United States China, ALIGN study, atrasentan, EGFR, endothelin A receptor antagonist, Fabhalta, Final ALIGN Data Support Vanrafia as Potential Foundational Therapy to Slow Kidney Function Decline in IgAN, IgA nephropathy, IgAN, iptacopan, kidney disease, Novartis, Novartis Advances IgA Nephropathy Portfolio with Positive Long-Term Phase III Results for Vanrafia, phase III clinical trial, proteinuria, RAS inhibitors, renal function decline, Ruchira Glaser, SGLT2 inhibitors, Vanrafia, zigakibart
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have found that the precise location of ATRX gene mutations plays a critical role in determining how neuroblastoma tumours behave and respond to treatment. Published in Neoplasia and supported by … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Arcobaleno Cancer Trust, ATRX gene, Cancer Research UK Clinician Scientist Fellowship, childhood cancer, differentiation therapy, Dr Federica Lorenzi, Dr Sally George, ICR, ICR Study Reveals How ATRX Mutation Location Influences Neuroblastoma Treatment Outcomes, Neoplasia, Neuroblastoma, New Research from The Institute of Cancer Research Advances Precision Approach to ATRX-Mutant Neuroblastoma, paediatric oncology, personalised medicine, Siobhans Superstar Legacy, stem cell modelling, The Institute of Cancer Research London, tumour genetics
(IN BRIEF) SGS has partnered with Berlin-based healthtech startup theblood to support the development and validation of diagnostic tools based on menstrual blood. Acting as an independent quality and validation partner, SGS will apply its pharmaceutical and bioanalytical expertise to … Read the full press release
Posted in Berlin, Business, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Berlin, Bioanalytical Sciences, clinical innovation, endometriosis, Fertility Health, healthtech, Menstrual Blood Diagnostics, Non Invasive Diagnostics, PCOS, Pharmaceutical Testing, polycystic ovary syndrome, Regulatory Validation, SGS, SGS partners with Berlin-based theblood to advance menstrual blood diagnostics in women’s health, theblood, theblood and SGS Collaborate to Establish Scientific and Regulatory Foundations for Menstrual Blood-Based Diagnostics, Women’s Health
(IN BRIEF) Sanofi has received Breakthrough Therapy designation from the U.S. FDA and orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for rilzabrutinib (Wayrilz) in warm autoimmune hemolytic anemia, based on data from the ongoing LUMINA 2 … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Retail, Science, Security & Safety, Technology
Tagged Breakthrough Therapy, BTK inhibitor, clinical trials, FDA, FDA Grants Breakthrough Status to Sanofi’s Rilzabrutinib for Rare Blood Disorder, IgG4-related disease, immune thrombocytopenia, Japanese Ministry of Health Labour and Welfare, Karin Knobe, LUMINA 2, LUMINA 3, orphan drug, rare diseases, rilzabrutinib, Sanofi, Sanofi Advances Rilzabrutinib with Breakthrough and Orphan Designations in wAIHA, sickle cell disease, Tailored Covalency®, wAIHA, warm autoimmune hemolytic anemia, Wayrilz
(IN BRIEF) GSK announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults in the EU with uncontrolled COPD characterised by raised blood eosinophils who are already receiving inhaled triple therapy, making it the … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged American Thoracic Society, blood eosinophils, COPD, CRSwNP, EGPA, emergency department visits, eosinophilic phenotype, European Commission, European Federation of Allergy and Airways Diseases Patients’ Associations, Exacerbations, GSK, GSK Expands Nucala’s European Indications with Landmark Approval for Uncontrolled COPD, GSK Strengthens Its Respiratory Portfolio as Nucala Receives EU Approval for Add-On COPD Treatment, HES, hospitalisations, IL-5, inhaled triple therapy, Kaivan Khavandi, MATINEE trial, mepolizumab, New England Journal of Medicine, Nucala, Phase III, respiratory medicine, Severe Asthma, Susanna Palkonen, type 2 inflammation
(IN BRIEF) The University of Liverpool has partnered with Boston-based BPGbio, Inc. to use artificial intelligence to accelerate the discovery of new medicines through its Civic HealthTech Innovation Zone, analysing large-scale healthcare data to uncover causal links in disease and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged artificial intelligence, BPGbio Inc, causal inference, CHI-Zone, Civic HealthTech Innovation Zone, Claire Eyers, drug discovery, Iain Buchan, Investment Zone Programme, Life Sciences Innovation Zone, Liverpool City Region, Mayor Steve Rotheram, multi-omics, NAi Bayesian AI, Niven Narain, Peter Green, precision medicine, University of Liverpool, University of Liverpool and BPGbio Launch Data-Driven Collaboration to Transform Mechanism-Based Drug Discovery
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have uncovered how the DNA repair enzyme XPF-ERCC1 is recruited to sites of damage and activated inside cells, resolving a long-standing question in molecular biology and providing structural insights that … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI in science, AlphaFold, Basil Greber, cancer research, cryogenic electron microscopy, DNA damage, DNA repair, genome integrity, ICR, Institute of Cancer Research, Medical Research Council, Molecular Biology, Nature Communications, New Structural Insights into XPF-ERCC1 Could Help Refine Future Cancer Treatments, SLX4, structural biology, XPF-ERCC1
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?